Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis

Modern Rheumatology

Volumn 20, Issue 6, 2010, Pages 580-587

  Chou, Chung Tei ^a   Tsai, Chang Youh ^a   Liang, Tung Hua ^b   Chang, Te Ming ^c   Lai, Chen Hung ^c   Wei, Cheng Chung ^d   Chen, Kun Hung ^e   Lin, Shih Chang ^e   Yu, Chia Li ^f   Liou, Lieh Bang ^g   Luo, Shue Fen ^g   Lee, Chyou Shen ^h   Hsue, Yin Tzu ⁱ   Huang, Chung Ming ^j   Chen, Jiunn Hong ^j   Lai, Ning Sheng ^k   Cheng, He Hsiung ^l   Cheng, Tien Tsai ^g   Lai, Han Ming ^g   Tsai, Wen Chan ^m   Yen, Jeng Hsien ^m   Lu, Ling Ying ⁿ   Chang, Chung Pei ^o   more..

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e CATHAY GENERAL HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^h MACKAY MEMORIAL HOSPITAL   (Taiwan)

ⁱ Christian Hospital   (Taiwan)

^j CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^k BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^l CHI MEI MEDICAL CENTER   (Taiwan)

^m KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁿ KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^o Memorial Hospital   (Taiwan)

more..

Author keywords

Ankylosing spondylitis; Chinese; Efficacy; Etanercept; Partial remission

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD ANALYSIS; BLOOD CHEMISTRY; CAUCASIAN; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RACE DIFFERENCE; URINALYSIS;

ADULT; ANTIRHEUMATIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH STATUS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RECOVERY OF FUNCTION; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650514551     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-010-0334-2     Document Type: Article

References (35)

1. M Dougados S van der Linden R Juhlin B Huitfeldt B Amor A Calin, et al. 1991 The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy Arthritis Rheum 34 1218 1227 1:STN:280:DyaK38%2FivFSqsA%3D%3D 1930310 10.1002/art.1780341003
2. MA Khan SM van der Linden 1990 Ankylosing spondylitis and other spondyloarthropathies Rheum Dis Clin North Am 16 551 579 1:STN:280: DyaK3M%2FhvVGlsA%3D%3D 2217958
3. CT Chou 2005 HLA-B27 and other related genes in ankylosing spondylitis in APLAR countries APLAR J Rheumatol 8 143 145 10.1111/j.1479-8077.2005.00159.x (Pubitemid 41807061)
4. S Gonzalez-Roces MV Alvarez S Gonzalez A Dieye H Makni DG Woodfield, et al. 1997 HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis Tissue Antigens 49 116 123 1:CAS:528:DyaK2sXhvV2is7c%3D 9062966 10.1111/j.1399-0039.1997.tb02724.x (Pubitemid 27084693)
5. RD Sturrock FD Hart 1974 Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis Ann Rheum Dis 33 129 131 1:STN:280:DyaE2c7ktVWksA%3D%3D 4595274 10.1136/ard.33.2.129
6. J Chen C Liu 2006 Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials J Rheumatol 33 722 731 1:CAS:528:DC%2BD28XksFCksLg%3D 16583475
7. E Toussirot P Lafforgue J Boucraut P Despieds A Schiano D Bernard, et al. 1994 Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies Rheumatol Int 13 175 180 1:STN:280:DyaK2c3mtFOksQ%3D%3D 8202660 10.1007/BF00390264 (Pubitemid 24111295)
8. J Gratacos A Collado X Filella R Sanmarti J Canete J Llena, et al. 1994 Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity Br J Rheumatol 33 927 931 1:STN:280:DyaK2M%2FgsF2qsQ%3D%3D 7921752 10.1093/rheumatology/33.10.927 (Pubitemid 24324807)
9. J Braun M Bollow L Neure E Seipelt F Seyrekbasan H Herbst, et al. 1995 Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis Arthritis Rheum 38 499 505 1:STN:280:DyaK2M3jsVSlug%3D%3D 7718003 10.1002/art.1780380407
10. J Gu J Kuipers E Maerker-Hermann D Yu 2000 Microarray gene expression profiles in spondyloarthropathy (SPA) mirror disease mediating processes [abstract] Arthritis Rheum 43 Suppl 9 S396
11. J Brandt H Haibel D Cornely W Golder J Gonzalez J Reddig, et al. 2000 Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab Arthritis Rheum 43 1346 1352 1:CAS:528:DC%2BD3cXkvFWnu70%3D 10857793 10.1002/1529-0131(200006)43: 6<1346::AID-ANR18>3.0.CO;2-E (Pubitemid 30416320)
12. JD Gorman KE Sack JC Davis 2002 Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor-α N Engl J Med 346 1349 1356 1:CAS:528:DC%2BD38Xjt1Shs70%3D 11986408 10.1056/NEJMoa012664 (Pubitemid 34754607)
13. JC Davis D van der Heijde J Braun M Douquados J Cush DO Cleqq, et al. 2003 Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis Arthritis Rheum 48 3230 3236 1:CAS:528: DC%2BD3sXpvVygtb0%3D 14613288 10.1002/art.11325 (Pubitemid 37409337)
14. A Calin BAC Dijkmans P Emery J Kalden M Leirisalo-Repo EM Mola, et al. 2004 Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis Ann Rheum Dis 63 1594 1600 1:CAS:528:DC%2BD2cXhtFaktbjM 15345498 10.1136/ard.2004.020875 (Pubitemid 39573687)
15. J Braun X Baraliakos J Brandt J Sieper 2005 Therapy of ankylosing spondylitis. Part II: Biological therapies in the spondyloarthritides Scand J Rheumatol 34 178 190 1:CAS:528:DC%2BD2MXnsVCgsL0%3D 16134723 10.1080/03009740510026599 (Pubitemid 40978638)
16. J Brandt J Listing H Haibel H Sörensen A Schwebig M Rudwaleit, et al. 2005 Long- term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis Rheumatology 44 342 348 1:CAS:528:DC%2BD2MXhslSksrw%3D 15561737 10.1093/rheumatology/keh475 (Pubitemid 40361291)
17. J Sieper X Baraliakos J Listing J Brandt H Haibel M Rudwaleit, et al. 2005 Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab Rheumatology 44 1525 1530 1:CAS:528:DC%2BD2MXht1GltrzN 16091396 10.1093/rheumatology/kei046 (Pubitemid 41742469)
18. D Heijde A Kivitz M Schiff J Sieper BA Dijakmans J Braun, et al. 2006 Efficacy and safety of adalimumab in patients with ankylosing spondylitis Arthritis Rheum 54 2136 2146 16802350 10.1002/art.21913 (Pubitemid 44051069)
19. R Lambert D Salonen P Rahman RD Inman RL Wong SG Einstein, et al. 2007 Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis Arthritis Rheum 56 4005 4014 1:CAS:528:DC%2BD1cXnt1Oluw%3D%3D 18050198 10.1002/art.23044 (Pubitemid 350262328)
20. CB Choi TJ Kim HJ Park WS Uhm JB Jun SC Bae, et al. 2008 Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy J Korean Med Sci 23 852 856 1:CAS:528:DC%2BD1cXhsVKmsrnJ 18955793 10.3346/jkms.2008.23.5.852
21. D Van der Heijde R Landewe S Einstein P Ory D Vosse L Ni, et al. 2008 Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept Arthritis Rheum 58 1324 1331 18438853 10.1002/art.23471 (Pubitemid 351705922)
22. SM Van der Linden HA Valkenburg A Cast 1984 Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria Arthritis Rheum 27 361 368 6231933 10.1002/art.1780270401
23. JJ Anderson G Baron D van der Heijde DT Felson M Douquados 2001 Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis Arthritis Rheum 44 1876 1886 1:STN:280:DC%2BD3MvmtlGntw%3D%3D 11508441 10.1002/1529-0131(200108)44:8<1876: :AID-ART326>3.0.CO;2-F (Pubitemid 32758236)
24. A Calin S Garrett H Whitelock LG Kennedy J O'Hea P Mallorie, et al. 1994 A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index J Rheumatol 21 2281 2285 1:STN:280:DyaK2M3htl2qsA%3D%3D 7699629
25. S Garrett T Jenkinson LG Kennedy H Whitelock P Gaisford A Calin, et al. 1994 A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index J Rheumatol 21 2286 2291 1:STN:280:DyaK2M3htl2qsQ%3D%3D 7699630
26. J Braun T Pham J Sieper J Davis S van der Linden M Dougados, et al. 2003 International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis Ann Rheum Dis 62 817 824 1:CAS:528:DC%2BD3sXns1SisLg%3D 12922952 10.1136/ard.62.9.817 (Pubitemid 37026490)
27. JC Wei RH Wong JH Huang CT Yu CT Chou MS Jan, et al. 2007 Evaluation of internal consistency and re-test reliability of bath ankylosing spondylitis indices in a large cohort of adult and juvenile spondylitis patients in Taiwan Clin Rheumatol 26 1685 1691 17286214 10.1007/s10067-007-0573-6
28. HS Howe L Zhao YW Song L Springer J Edmonds J Gu, et al. 2007 Seronegative spondyloarthropathy-studies from the Asia pacific region Ann Acad Med Singapore 36 135 141 17364081 (Pubitemid 46640266)
29. TE Feltkamp A Mardjuadi F Huang CT Chou 2001 Spondyloarthropathies in eastern Asia Curr Opin Rheumatol 13 285 290 1:STN:280:DC%2BD3MrhsVWitQ%3D%3D 11555729 10.1097/00002281-200107000-00007 (Pubitemid 32831819)
30. CT Chou 2006 The clinical application of etanercept in Chinese patients with rheumatic disease Mod Rheumatol 16 206 213 1:CAS:528:DC%2BD28XotVymsLY%3D 16906369 10.1007/s10165-006-0486-2 (Pubitemid 44227339)
31. F Huang J Gu W Zhao J Zhu J Zhang DT Yu 2002 One-year-open-label trial of thalidomide in ankylosing spondylitis Arthritis Rheum 47 249 254 1:CAS:528:DC%2BD38Xlt1eisro%3D 12115153 10.1002/art.10396 (Pubitemid 34627691)
32. D Van der Heijde B Dijkmans P Geusens J Sieper K DeWoody P Williamson for the Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group, et al. 2005 Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT) Arthritis Rheum 52 582 591 15692973 10.1002/art.20852 (Pubitemid 40216323)
33. JC Davis D Heijde M Dougados JM Woolley 2005 Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy Arthritis Rheum 53 494 501 16082640 10.1002/art.21330 (Pubitemid 41278913)
34. S Visvanathan CL Wagner JC Marini D Baker T Gathany J Han, et al. 2008 Inflammatory biomarkers, disease activity, and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab Ann Rheum Dis 67 511 517 1:CAS:528:DC%2BD1cXltlSksrw%3D 17644552 10.1136/ard.2007.071605 (Pubitemid 351498433)
35. X Baraliakos J Brandt J Listing H Haibel H Sörensen M Rudwaleit, et al. 2005 Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data Arthritis Rheum 53 856 863 1:CAS:528:DC%2BD28Xks1Wiuw%3D%3D 16342093 10.1002/art.21588 (Pubitemid 41811126)